Intellijoint HIP features two miniature sensors which are placed in the sterile field and communicate with a portable display.
Controlled by the surgeon, it quantifies the measurements, often left to subjective judgment, required for selecting and positioning hip implants.
Intellijoint CEO Armen Bakirtzian said: "We’re already approved in Canada, now we can begin marketing Intellijoint HIP to hospitals and orthopedic surgeons in the United States.
"In the US, similar to Canada, our initial marketing plan is to work closely with certain leading surgeons and hospitals in specific geographic areas. In parallel, we are solidifying alliances with major implant companies while continuing to expand our product line."
The company claims that Intellijoint HIP helps surgeons in measuring the correct leg length and hip offset, which are said to be the main sources of patient dissatisfaction in hip replacement.
